1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum

Journal of Neuroscience Research

Volumn 87, Issue 3, 2009, Pages 723-732

  Sanchez, Begoña ^a   Relova, Jose L ^a   Gallego, Rosalia ^a   Ben Batalla, Isabel ^a   Perez Fernandez, Roman ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

6 OHDA; GDNF; Parkinson's disease; TH; Vitamin D

Indexed keywords

CALCITRIOL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; MALE; NERVE ENDING; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PERIKARYON; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA;

ANIMALS; BLOTTING, WESTERN; CALCITRIOL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; MALE; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 62849099010     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21878     Document Type: Article

References (34)

1. Aoi M, Date I, Tomita S, Ohmoto T. 2000. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci Res 36:319-325.
2. Aoi M, Date I, Tomita S, Ohmoto T. 2001. Single administration of GDNF into the striatum induced protection and repair of the nigrostriatal dopaminergic system in the intrastriatal 6-hydroxydopamine injection model of hemiparkinsonism. Restor Neurol Neurosci 17:31-38.
3. Barroso-Chinea P, Cruz-Muros I, Aymerich MS, Rodriguez-Diaz M, Afonso-Oramas D, Lanciego JL, Gonzalo-Hernandez T. 2005. Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells. Eur J Neurosci 21:1815-1827.
4. Björklund A, Rosenblad C, Winkler C, Kirik D. 1997. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 4:186-200.
5. Derex L, Trouillas P. 1997. Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy. Mov Disod 12:612-613.
6. Dietz GPH, Valbuena PC, Dietz B, Meuer K, Müller P, Weishaupt JH, Bähr M. 2006. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease. Brain Res 1082:61-66.
7. Dunnett SB, Bjorklund A. 1999. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399:A32-A39.
8. 3 uptake by canine and rodent brain. Am J Physiol Endocrinol Metab 244:E266-E271.
9. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA. 1996. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255.
10. Granholm AC, Reyland M, Albeck D, Sanders L, Gerhardt G, Hoernig G, Shen L, Westphal H, Hoffer B. 2000. Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J Neurosci 20:3182-3190.
11. Gurlek A, Pittelkow MR, Kumar R. 2002. Modulation of growth factor/ cytokine synthesis and signaling by 1α-dihydroxyvitamin D3: Implications in cell growth and differentiation. Endocrine Rev 23:763-786.
12. 3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology 40:761-771.
13. Kilic Ü, Kilic E, Dietz GPH, Bähr M. 2003. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 34:1304-1310.
14. Kilic Ü, Kilic E, Dietz GPH, Bähr M. 2004. The TAT protein transduction domain enhances the neuroprotective effect of GDNF after optic nerve transection. Neurodegener Dis 1:44-49.
15. Kramer ER, Aron L, Ramakers GM, Seitz S, Zhuang X, Beyer K, Smidt MP, Klein R. 2007. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol 5:e39 [doi:10.1371/journal.pbio.0050039].
16. López-Martín E, Relova-Quinteiro JL, Gallego-Gómez R, Peleteiro-Fernández M, Jorge-Barreiro FJ, Ares-Pena FJ. 2006. GSM radiation triggers seizures and increases cerebral c-Fos positivity in rats pretreated with subconvulsive doses of picrotoxin. Neurosci Lett 398:139-144.
17. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. 1993. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
18. Lindholm P, Voutilainen MH, Lauren J, Peranen J, Leppanen VM, Andressoo JO, Lindahl M, Janhunen S, Kalkkinen N, Timmusk T, Tuominen RK, Saarma M. 2007. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448:73-78.
19. 3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport 7:2171-2175.
20. Paille V, Henry V, Lescaudron L, Brachet P, Damier P. 2007. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov Disord 22:533-539.
21. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates,2nd ed. San Diego: Academic Press.
22. Rind HB, Von Barthheld CS. 2002. Anterograde axonal transport of internalized GDNF in sensory and motor neurons. Neuroreport 13:659-664.
23. Rosenblad C, Kirik D, Devaux B, Moffat B, Phllips HS, Björklund A. 1999. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 11:1554-1566.
24. Russel FD, Koishi K, Jiang Y, McLennan LS. 2000. Anterograde axonal transport of glial cell line-derived neurotrophic factor and its receptors in rat hypoglossal nerve. Neuroscience 97:575-580.
25. 3 increases striatal GDNF MRNA and protein expression in adult rats. Brain Res Mol Brain Res 108:143-146.
26. Sato Y, Kikuyama M, Oizumi K. 1997. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 49:1273-1278.
27. Siegel GJ, Chauhan NB. 2000. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Rev 33:199-227.
28. Smith MP, Fletcher-Turner A, Yurek DM, Cass WA. 2006. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res 31:533-539.
29. Tang YP, Ma YL, Chao CC, Chen KY, Lee EHY. 1998. Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (2)-deprenyl and melatonin treatments. J Neurosci Res 53:593-604.
30. Tomac A, Lindqvist E, Lin LFH, Ogren SO, Young D, Hoffer BJ, Olson L. 1995. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339.
31. Verity AN, Wyatt TL, Lee W, Hajos B, Baecker PA, Eglen RM, Johnson RM. 1999. Differential regulation of glial cell line-derived neurotrophic factor (GDNF) expression in human neuroblastoma and glioblastoma cell lines. J Neurosci Res 55:187-197.
32. 3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res 904:67-75.
33. 3 attenuates cortical infraction induced by middle cerebral arterial ligation in rats. Neuropharmacology 39:873-880.
34. Yurek DM, Fletcher-Turner A. 2001. Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion. Brain Res 891:228-235.